Physician profile
Adrian Harry Shandling
NPI 1386640522
$23,631.82
in general payments reported to CMS, 2019-2025
60 companies · $2,763 in 2025
The $2,763 reported for 2025 was more than what 87% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,014 · 2020: $4,014 · 2021: $2,645 · 2022: $3,109 · 2023: $2,819 · 2024: $4,268 · 2025: $2,763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,106 · Travel and Lodging: $722 · Education: $21.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,106.37 |
| Travel and Lodging | $722.00 |
| Education | $21.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,115.65 | 2019-2025 | |
| Medtronic, INC. | $1,838.06 | 2022-2025 | Micra, Pulseselect, Na |
| Medtronic Vascular, INC. | $1,766.20 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,364.13 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $1,273.97 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $1,258.18 | 2019-2025 | Verquvo, Winrevair, Capvaxive |
| Pfizer INC. | $1,200.03 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,118.85 | 2019-2025 | Wainua, Farxiga, Brilinta |
| Janssen Pharmaceuticals, INC | $1,070.72 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $994.79 | 2021-2025 | Ozempic, Wegovy |
| Alnylam Pharmaceuticals INC. | $984.40 | 2019-2025 | Amvuttra |
| Amgen INC. | $972.75 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $762.43 | 2019-2025 | Camzyos, Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $606.23 | 2021-2025 | |
| Medicure Pharma INC. | $546.15 | 2020-2022 |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $515.01 | 2019-2024 | Tyvaso |
| Regeneron Healthcare Solutions, INC. | $485.13 | 2019-2025 | Evkeeza, Praluent |
| Esperion Therapeutics, INC. | $451.78 | 2020-2025 | Nexletol |
| Atricure, INC. | $348.10 | 2019-2025 | Atriclip Laa Exclusion System |
| Kowa Pharmaceuticals America, INC. | $316.36 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $301.98 | 2019-2025 | Opsumit, Uptravi |
| Boston Scientific Corporation | $293.50 | 2019-2025 | Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $264.14 | 2019-2025 | Lifevest |
| Amarin Pharma, INC. | $263.22 | 2019-2022 | |
| Biosense Webster, INC. | $240.84 | 2021-2025 | Carto 3, Octaray Mapping Catheter |
| Abiomed | $170.44 | 2025 | |
| Akcea Therapeutics, INC. | $167.33 | 2019-2021 | |
| Gilead Sciences, INC. | $145.27 | 2019 | |
| Irhythm Technologies, INC. | $141.87 | 2019-2022 | |
| Scpharmaceuticals INC. | $127.13 | 2023-2025 | |
| Impulse Dynamics (USA) INC. | $126.56 | 2023 | Optimizer |
| Kiniksa Pharmaceuticals International, Plc | $118.73 | 2024 | Arcalyst |
| Bardy Diagnostics, INC. | $117.84 | 2020-2022 | |
| Lundbeck LLC | $113.06 | 2019-2021 | |
| Philips North America LLC | $111.85 | 2020-2022 | |
| Kestra Medical Technology Services, INC. | $109.27 | 2022-2025 | Assure Wcd |
| Kiniksa Pharmaceuticals, LTD. | $90.62 | 2022-2023 | Arcalyst |
| Medical Device Business Services, INC. | $82.49 | 2019 | |
| Abbott Laboratories | $70.34 | 2019-2022 | |
| Glaxosmithkline, LLC. | $66.48 | 2019-2025 | Shingrix, Arexvy |
| Bridgebio Pharma, INC. | $64.61 | 2025 | Attruby |
| Edwards Lifesciences Corporation | $44.66 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Heartflow, INC. | $40.47 | 2025 | |
| Recor Medical INC | $39.25 | 2025 | Paradise Ultrasound Renal Denervation System |
| Celgene Corporation | $39.20 | 2024 | Camzyos |
| Biotronik INC. | $29.67 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $28.43 | 2024 | |
| Circassia INC. | $25.56 | 2019 | |
| Sobi, INC | $25.06 | 2021 | |
| Chiesi USA, INC. | $23.19 | 2025 | Juxtapid |
| Eisai INC. | $22.76 | 2021 | |
| Alexion Pharmaceuticals, INC. | $20.40 | 2021 | |
| Lilly USA, LLC | $16.91 | 2025 | Mounjaro, Zepbound |
| Genzyme Corporation | $16.55 | 2019 | |
| W. L. Gore & Associates, INC. | $15.60 | 2021 | |
| Lemaitre Vascular, INC. | $14.84 | 2019 | |
| Portola Pharmaceuticals, LLC | $13.69 | 2019 | |
| Infobionic, INC | $13.47 | 2024 | Mome Device |
| Cmp Pharma, INC. | $13.17 | 2021 | |
| Allergan, INC. | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrian Shandling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.